probable result of the overuse of pressurized aerosols, raised hardly a ripple of interest in the public sector.
Personal contact between the Committee's staff and members of the medical profession who have reported adverse reactions or who have enquired about them has proved to be of incalculable value. As a matter of routine, each doctor reporting a reaction receives a summary of all the reactions that have been previously reported with the relevant group of drugs.
As soon as possible, the Committee intends to publish the whole of its Register of Adverse Reactions so that doctors may be apprised of the considerable amount of data that have already accumulated.
The Committee has encouraged doctors to make use of the available data. Recently, for example, an investigator studying the problem of post-anxesthetic jaundice discovered that as many detailed case reports were found in the Committee's files as in the whole of the world literature on this topic. Summary Three major activities of a drug monitor, early warning, follow up and feed-back, are aimed at detecting and investigating drug safety problems within the limits imposed by the available staff and equipment, stimulating research by others and providing an information service for prescribers.
Among the limitations of drug monitoring based on voluntary reports, that imposed by the comparative rarity of the more serious reactions, as a result of which very large populations have to be studied, is seen to be the most important. Adverse reactions are seriously under-reported but, in spite of this, the drug monitor is capable of detecting more new drug safety problems than it can evaluate. Workers in many disciplines are encouraged to take an active part in the evaluation of the drug safety problems that come to light as a result of operating the drug monitor. Studies undertaken by the Committee on Safety of Drugs have played a major part in establishing the relationship between oral contraceptives and thromboembolic disease. The epidemiological and statistical problems involved in four such studies (Cahal 1965 , Jick et al. 1969 ) were discussed. Particular attention was paid to a recent analysis , which utilized routinely submitted reports of suspected adverse reactions to oral contraceptives, and demonstrated that the risk of thromboembolism is related to the oestrogen content of the preparations.
